Cardiovascular diseases (CVDs) are the single leading cause of death globally.Diabetes elevates the risk for cardiovascular disease (CVD) complications, particularly atherosclerotic vascular disease. Cardiovascular events remain the major cause of death for those with diabetes, accounting for about 70% of all deaths in the patient population.

Lipoprotein (a) is a low-density lipoprotein (LDL) particle with the glycoprotein apo(a) covalently bound to apo B-100. Apo(a) is a highly glycosylated hydrophilic apolipoprotein which is synthesized by the liver. Apo(a) is structurally homologous to the plasma protein plasminogen which is involved in the lysis of clots.Strong evidence in epidemiological, genetic, and prospective cohort studies verified that circulating lp(a) levels were associated with the presence of cardiovascular disease (CVD). Lipoprotein (a) is an emerging cardiovascular risk factor which is also associated with diabetes.

In the present study CVD risk in type 2 diabetes will be assessed and categorized into those at   low, moderate, and high CVD risk by calculating various risk scores methods that are: ¹⁷

(1) FRAMINGHAM RISK SCORE

(2) QRISK3

(3) INTERHEART RISK SCORE

Hospital based cross sectional study will be carried out in Department of Biochemistry of RUHS College of Medical Sciences & associated hospital, Jaipur, over a period of 1.5 years. 90 participants of either gender with type 2 DM will be recruited attending medicine OPD and IPD  after written informed consent and ethics approval from the institutional ethics committee. normal distribution=1.96, absolute precision =9%  prevalence =25% so so sample size will be taken approximate  90. and in this study patients will be included 30 to 70 years age of either gender of type 2 diabetes mellitus .